Challenges of dual-targeted CAR T-cell therapy
Reengineering Chimeric Antigen Receptor T Cells for Targeted Therapy of Autoimmunity
ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa results
Dr. Renier Brentjens on Genetically Engineering Tumor-Targeted T Cells
PSMA - Targeted T Cells for the Treatment of Prostate Cancer
Neoantigen-targeted CD8+ T-cell responses with PD-1 blockade therapy
PSMA targeted CAR-T therapy for prostate cancer
Dr. Brentjens on CD19-Targeted T Cells in CLL and ALL
T-Bar Rows: Targeted Thickness and Strength #t-barrows #backthickness #strengthbuilding
Unmet needs in T-ALL: targeted therapies & managing relapse
Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma
Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myeloma
MB-106 as a novel CD20-targeted CAR-T treatment in R/R B-NHL
Phase I study of CD22-targeted CAR-T therapy in patients with CD19-negative B-ALL
Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma
Promise of GPRC5D-targeted CAR-T therapies in multiple myeloma
HER2-targeted CAR T-cell therapy safe, with promising antitumor activity in patients with advanc...
Dr. Adusumilli on the Rationale for Mesothelin-Targeted CAR T-Cell Therapy
Dr. Wierda on Using CD19-Targeted CAR T Cells in CLL
Current research on CD19 targeted CAR T-cells in relapsed B-cell ALL
